Kardigan Inc (KARD) Stock Analysis
Verdict: AVOID
Negative equity and a cash runway of less than 9 months make KARD a high-risk dilution candidate despite its AI cardiovascular platform.
Investment score: 32/100
Analysis as of
Is Kardigan Inc stock worth reviewing? AI model thesis
A pre-revenue biotech with a dangerous burn rate and negative equity.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Kardigan Inc opportunities and risks
What speaks for KARD
- AI Cardiac Intelligence Platform
What speaks against KARD
- Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CDXI | n/a | 0.0x | n/a | 63.6% | -938.0% | -2257745.0% |
| VOQP | n/a | 0.0x | n/a | 0.0% | 0.0% | -48151.1% |
| LLY | 43.0x | 15.8x | 35.3x | 83.5% | 35.0% | 1.2% |
| Peer median | n/a | 0.0x | n/a | 63.6% | 0.0% | -48151.1% |
Frequently asked questions about Kardigan Inc (KARD)
Is KARD stock a good investment?
The cached TradeMates AI model rates Kardigan Inc as AVOID with an investment score of 32/100. A pre-revenue biotech with a dangerous burn rate and negative equity. This is algorithmic model output, not personal investment advice.
Is KARD stock a buy?
The TradeMates model verdict for KARD is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.